Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 462

1.

Compound haploinsufficiency of Dok2 and Dusp4 promotes lung tumorigenesis.

Chen M, Zhang J, Berger AH, Diolombi MS, Ng C, Fung J, Bronson RT, Castillo-Martin M, Thin TH, Cordon-Cardo C, Plevin R, Pandolfi PP.

J Clin Invest. 2018 Nov 26. pii: 99699. doi: 10.1172/JCI99699. [Epub ahead of print]

2.

ZBTB7A governs estrogen receptor alpha expression in breast cancer.

Molloy ME, Lewinska M, Williamson AK, Nguyen TT, Kuser-Abali G, Gong L, Yan J, Little JB, Pandolfi PP, Yuan ZM.

J Mol Cell Biol. 2018 Aug 1;10(4):273-284. doi: 10.1093/jmcb/mjy020.

PMID:
30265334
3.

Inactivation of PBX3 and HOXA9 by down-regulating H3K79 methylation represses NPM1-mutated leukemic cell survival.

Zhang W, Zhao C, Zhao J, Zhu Y, Weng X, Chen Q, Sun H, Mi JQ, Li J, Zhu J, Chen Z, Pandolfi PP, Chen S, Yan X, Xu J.

Theranostics. 2018 Jul 30;8(16):4359-4371. doi: 10.7150/thno.26900. eCollection 2018.

4.

The Mouse Hospital and Its Integration in Ultra-Precision Approaches to Cancer Care.

Clohessy JG, Pandolfi PP.

Front Oncol. 2018 Aug 28;8:340. doi: 10.3389/fonc.2018.00340. eCollection 2018.

5.

Loss of LDAH associated with prostate cancer and hearing loss.

Currall BB, Chen M, Sallari RC, Cotter M, Wong KE, Robertson NG, Penney KL, Lunardi A, Reschke M, Hickox AE, Yin Y, Wong GT, Fung J, Brown KK, Williamson RE, Sinnott-Armstrong NA, Kammin T, Ivanov A, Zepeda Mendoza CJ, Shen J, Quade BJ, Signoretti S, Arnos KS, Banks AS, Patsopoulos N, Charles Liberman M, Kellis M, Pandolfi PP, Morton CC.

Hum Mol Genet. 2018 Aug 30. doi: 10.1093/hmg/ddy310. [Epub ahead of print]

PMID:
30169630
6.

The functions and regulation of the PTEN tumour suppressor: new modes and prospects.

Lee YR, Chen M, Pandolfi PP.

Nat Rev Mol Cell Biol. 2018 Sep;19(9):547-562. doi: 10.1038/s41580-018-0015-0. Review.

PMID:
29858604
7.

An Integrated Genome-wide CRISPRa Approach to Functionalize lncRNAs in Drug Resistance.

Bester AC, Lee JD, Chavez A, Lee YR, Nachmani D, Vora S, Victor J, Sauvageau M, Monteleone E, Rinn JL, Provero P, Church GM, Clohessy JG, Pandolfi PP.

Cell. 2018 Apr 19;173(3):649-664.e20. doi: 10.1016/j.cell.2018.03.052.

PMID:
29677511
8.

The p85 isoform of the kinase S6K1 functions as a secreted oncoprotein to facilitate cell migration and tumor growth.

Zhang J, Guo J, Qin X, Wang B, Zhang L, Wang Y, Gan W, Pandolfi PP, Chen W, Wei W.

Sci Signal. 2018 Mar 27;11(523). pii: eaao1052. doi: 10.1126/scisignal.aao1052.

PMID:
29588411
9.

The mTOR Targets 4E-BP1/2 Restrain Tumor Growth and Promote Hypoxia Tolerance in PTEN-driven Prostate Cancer.

Ding M, Van der Kwast TH, Vellanki RN, Foltz WD, McKee TD, Sonenberg N, Pandolfi PP, Koritzinsky M, Wouters BG.

Mol Cancer Res. 2018 Apr;16(4):682-695. doi: 10.1158/1541-7786.MCR-17-0696. Epub 2018 Feb 16.

PMID:
29453322
10.

An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer.

Chen M, Zhang J, Sampieri K, Clohessy JG, Mendez L, Gonzalez-Billalabeitia E, Liu XS, Lee YR, Fung J, Katon JM, Menon AV, Webster KA, Ng C, Palumbieri MD, Diolombi MS, Breitkopf SB, Teruya-Feldstein J, Signoretti S, Bronson RT, Asara JM, Castillo-Martin M, Cordon-Cardo C, Pandolfi PP.

Nat Genet. 2018 Feb;50(2):206-218. doi: 10.1038/s41588-017-0027-2. Epub 2018 Jan 15.

PMID:
29335545
11.

Deregulated PP1α phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism.

Chen M, Wan L, Zhang J, Zhang J, Mendez L, Clohessy JG, Berry K, Victor J, Yin Q, Zhu Y, Wei W, Pandolfi PP.

Nat Commun. 2018 Jan 15;9(1):159. doi: 10.1038/s41467-017-02272-y.

12.

Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms.

Bezzi M, Seitzer N, Ishikawa T, Reschke M, Chen M, Wang G, Mitchell C, Ng C, Katon J, Lunardi A, Signoretti S, Clohessy JG, Zhang J, Pandolfi PP.

Nat Med. 2018 Feb;24(2):165-175. doi: 10.1038/nm.4463. Epub 2018 Jan 8.

PMID:
29309058
13.

A non-cell-autonomous role for Pml in the maintenance of leukemia from the niche.

Guarnerio J, Mendez LM, Asada N, Menon AV, Fung J, Berry K, Frenette PS, Ito K, Pandolfi PP.

Nat Commun. 2018 Jan 4;9(1):66. doi: 10.1038/s41467-017-02427-x.

14.

Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure.

de Thé H, Pandolfi PP, Chen Z.

Cancer Cell. 2017 Nov 13;32(5):552-560. doi: 10.1016/j.ccell.2017.10.002. Review.

15.

A circular twist on microRNA regulation.

Bezzi M, Guarnerio J, Pandolfi PP.

Cell Res. 2017 Dec;27(12):1401-1402. doi: 10.1038/cr.2017.136. Epub 2017 Oct 31.

16.

Preclinical and Coclinical Studies in Prostate Cancer.

Chen M, Pandolfi PP.

Cold Spring Harb Perspect Med. 2018 Apr 2;8(4). pii: a030544. doi: 10.1101/cshperspect.a030544. Review.

PMID:
29038335
17.

Identification of competing endogenous RNAs of the tumor suppressor gene PTEN: A probabilistic approach.

Zarringhalam K, Tay Y, Kulkarni P, Bester AC, Pandolfi PP, Kulkarni RV.

Sci Rep. 2017 Aug 10;7(1):7755. doi: 10.1038/s41598-017-08209-1.

18.

Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling.

Tripodo C, Burocchi A, Piccaluga PP, Chiodoni C, Portararo P, Cappetti B, Botti L, Gulino A, Isidori A, Liso A, Visani G, Martelli MP, Falini B, Pandolfi PP, Colombo MP, Sangaletti S.

Cancer Res. 2017 Jul 1;77(13):3685-3699. doi: 10.1158/0008-5472.CAN-17-1098. Epub 2017 May 23.

19.

Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation.

van de Ven AL, Tangutoori S, Baldwin P, Qiao J, Gharagouzloo C, Seitzer N, Clohessy JG, Makrigiorgos GM, Cormack R, Pandolfi PP, Sridhar S.

Mol Cancer Ther. 2017 Jul;16(7):1279-1289. doi: 10.1158/1535-7163.MCT-16-0740. Epub 2017 May 12.

20.

Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones.

Carrà G, Panuzzo C, Torti D, Parvis G, Crivellaro S, Familiari U, Volante M, Morena D, Lingua MF, Brancaccio M, Guerrasio A, Pandolfi PP, Saglio G, Taulli R, Morotti A.

Oncotarget. 2017 May 30;8(22):35508-35522. doi: 10.18632/oncotarget.16348.

Supplemental Content

Loading ...
Support Center